These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22505016)

  • 1. Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells.
    Salhia B; Van Cott C; Tegeler T; Polpitiya A; Duquette RA; Gale M; Hostteter G; Petritis K; Carpten J
    Hum Mutat; 2012 Aug; 33(8):1216-27. PubMed ID: 22505016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
    Mancini ML; Lien EC; Toker A
    Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
    Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
    Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
    De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
    Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT1(E17K) in human solid tumours.
    Bleeker FE; Felicioni L; Buttitta F; Lamba S; Cardone L; Rodolfo M; Scarpa A; Leenstra S; Frattini M; Barbareschi M; Grammastro MD; Sciarrotta MG; Zanon C; Marchetti A; Bardelli A
    Oncogene; 2008 Sep; 27(42):5648-50. PubMed ID: 18504432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
    Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
    Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inappropriate P-cadherin expression in the mouse mammary epithelium is compatible with normal mammary gland function.
    Radice GL; Sauer CL; Kostetskii I; Peralta Soler A; Knudsen KA
    Differentiation; 2003 Aug; 71(6):361-73. PubMed ID: 12919105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells.
    Lucas JJ; Domenico J; Gelfand EW
    Mol Cancer Res; 2004 Feb; 2(2):105-14. PubMed ID: 14985467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.
    Malanga D; Scrima M; De Marco C; Fabiani F; De Rosa N; De Gisi S; Malara N; Savino R; Rocco G; Chiappetta G; Franco R; Tirino V; Pirozzi G; Viglietto G
    Cell Cycle; 2008 Mar; 7(5):665-9. PubMed ID: 18256540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
    Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines.
    Sivko GS; DeWille JW
    J Cell Biochem; 2004 Nov; 93(4):830-43. PubMed ID: 15389879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
    Gao SP; Kiliti AJ; Zhang K; Vasani N; Mao N; Jordan E; Wise HC; Shrestha Bhattarai T; Hu W; Dorso M; Rodrigues JA; Kim K; Hanrahan AJ; Razavi P; Carver B; Chandarlapaty S; Reis-Filho JS; Taylor BS; Solit DB
    Mol Cancer Res; 2021 Apr; 19(4):573-584. PubMed ID: 33303690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.
    Landgraf KE; Pilling C; Falke JJ
    Biochemistry; 2008 Nov; 47(47):12260-9. PubMed ID: 18954143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast.
    Stingl J; Eaves CJ; Kuusk U; Emerman JT
    Differentiation; 1998 Aug; 63(4):201-13. PubMed ID: 9745711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis.
    Bennett HL; Brummer T; Jeanes A; Yap AS; Daly RJ
    Oncogene; 2008 Apr; 27(19):2693-704. PubMed ID: 17998934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of geminin stimulates the growth of mammary epithelial cells and is a frequent event in human tumors.
    Montanari M; Boninsegna A; Faraglia B; Coco C; Giordano A; Cittadini A; Sgambato A
    J Cell Physiol; 2005 Jan; 202(1):215-22. PubMed ID: 15389519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
    Chen J; Miller EM; Gallo KA
    Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
    Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
    Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
    Kim MS; Jeong EG; Yoo NJ; Lee SH
    Br J Cancer; 2008 May; 98(9):1533-5. PubMed ID: 18392055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.